创新药回调或现吸筹机会？恒生创新药ETF（159316）盘中逆势获1900万份净申购

Group 1 - The Hong Kong stock market experienced fluctuations today, with the innovative drug sector undergoing a significant correction, as the Hang Seng Innovative Drug Index fell by 3.9% by 14:00 [1] - The Hang Seng Innovative Drug ETF (159316) recorded a trading volume of nearly 400 million yuan, with a net subscription of 19 million shares. Over the past month, the ETF has seen a net inflow exceeding 500 million yuan, bringing its latest scale to over 1 billion yuan, marking a historical high [1] - Shanghai recently introduced measures to promote the high-quality development of commercial health insurance to support innovation in the biopharmaceutical industry, which includes expanding the coverage of commercial health insurance to include new medical technologies, drugs, devices, and consumables [1] Group 2 - The Hang Seng Innovative Drug Index announced a revision to its compilation scheme, which will exclude CXO companies and focus on core innovative drug companies. The revised rules will take effect on August 11, making it the first index with a "purity" of 100% for innovative drugs among the ETFs it tracks [1] - The Hang Seng Innovative Drug ETF (159316) is the only ETF tracking this index, providing investors with a streamlined way to invest in leading innovative pharmaceutical companies [1]